|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for TNFRSF8(NM_001243.4) Search again
Product ID:
HQP022753
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
CD30, D1S166E, Ki-1
Gene Description:
TNF receptor superfamily member 8
Target Gene Accession:
NM_001243.4(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Validated result:
|
|
| A | B |
|
Each All-in-One™ qPCR Primer is experimentally validated to yield a single dissociation curve peak and to generate a single amplification of the correct size for the targeted gene. A cDNA Pool, containing reverse transcript products of 8 different human tissue total RNA(Liver, Testis,Muscle,Thyroid,Brain,Spleen,Stomach,Small Intestine)),was used as the qPCR validation template. qPCR was performed using 0.2 µM primer with 2XAll-in-One™ qPCR Mix (Catalog#: QP001,QP002,QP004,QP005). Reactions were incubated for 10min. at 95°C, followed by 40 cycles of 95°C for 10 sec.; 60°C, 20 sec. and 72°C, 15sec. using Bio-Rad iQ5™ Instrument. At the end of the last cycle, temperature was increased from 72 to 95°C to produce a melting curve. Panel A: Validated Result for Amplification Curve; Panel B: Validated Result for Melting Curve. |
|
Summary
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. This receptor is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. [provided by RefSeq].
Gene References into function
- expression in T cells up-regulated by CD30L
- Differential expression of CD30 and p80 between peripheral blood and bone marrow lymphoma cells is a property of the small cell variant of anaplastic large cell lymphoma.
- constitutive signaling by CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells
- Single-cell analysis of CD30+ cells in lymphomatoid papulosis demonstrates a common clonal T-cell origin.
- CD30, but not 4-1BB or OX-40, is preferentially induced by alloantigen, suggesting that CD30 may be important in human alloimmune responses
- REVIEW: CD30-mediated signal transduction pathways and possible roles in Hodgkins disease and anaplastic large cell lymphoma
- only in a subset of both benign and malignant thyroid nodules the interleukin-6/interleukin-6 receptor signal could be induced by the CD30 ligand/CD30
- Results suggest that the N- and C-termini of the extracellular portion of CD30 are in close vicinity of each other, suggesting a flower-like structure for the membrane-bound homotrimeric CD30 molecule.
- REVIEW: the biological link between 2 characteristic features of H-RS cells: CD30 overexpression and constitutive NF-kappaB activation
- REVIEW: role of CD30 in determining the activity of T cells toward synthesis of cytokines and involvement in reactions of Th2 characteristics.
- Data suggest that overexpression and binding of JunB to the AP-1 site may relieve the repression of the core promoter by CD30 in Hodgkin-Redd Sternberg cells, which provide one basis for the constitutive overexpression of CD30 in Hodgkin's lymphoma.
- the anti-inflammatory activity of IL-4-producing CD30+ CD4+ T cells in rheumatoid arthritis may be limited in the synovium due to a poor induction of surface CD30 and a susceptibility to CD30-mediated cell death.
- Increased levels of CD30 is associted with ineffective antitumor immunity in Hodgkin's disease
- CD30 shedding is stimulated by an elevated local availability of cysteine-rich domain 2 or 5, possibly by forming a docking station for the releasing enzyme through substrate aggregation.
- CD30-regulated expression of cIAP1 & cIAP2 is mediated by NFkappaB & correlates with protection from etoposide-induced apoptosis. CD30-induced signaling may have a major impact on the clinical outcome of patients with anaplastic large cell lymphoma cells
- CD30 can act as both a positive and negative growth factor depending on cell type
- CD30 activation plays a role in eosinophil apoptosis.
- results suggest that CD30-mediated apoptosis is not a common feature in this cell type and that p38 MAP kinase is involved in CD30-mediated singal transduction.
- Immunity to CD30 could play a role in Marek disease lymphoma regression.
- The results showed that: (1) epithelial cells in the developing intestinal crypts express the CD30 (Ki-1) antigen; (2) CD30 expression in these epithelial cells is higher in cases of hormonal administration than in normal gestation.
- CD30 transformed cells trigger the noncanonical NF-kappaB activation pathway, and suggest that deregulated CD30 signaling contributes to the neoplastic features of Hodgkin Reed Sternberg cells.
- Elevated CD30 expression is considered one of the causes of constitutive NF-kappaB activation in adult T-cell Leukemia (ATL) cells, and may be involved in ATL development.
- Pretransplant soluble CD30 is a more accurate predictor of acute rejection when compared with panel reactive antibodiees in kidney transplantation.
- This marker provides a risk factor for chronic kidney transplant rejection independent of classical immunological risk factors and may be down-regulated using Tacrolimus treatment.
- Presence of CD30 T cells correlated with preservation of graft function following lung transplantation.
- CD30 is a costimulatory molecule and marker of a regulatory subpopulation of DCs which induces and modulates immune cells involved in the maintenance of the balance between TH1/TH2 immune responses and tolerance.
- High pre-transplant levels of soluble CD30 are associated with antibody-mediated rejection of Kidney Transplantation
- Expression patterns of the tumor marker CD30, which is a cell surface antigen expressed Hodgkin's lymphoma in mice.
- (p52)2/Bcl-3P ternary complex, which is specifically induced in CD30-stimulated anaplasstic larage cell lymphoma, can modulate expression of apoptosis-related genes regulated by NF-kappaB.
- intercellular adhesion molecule 1 promoter was activated by the C-terminal region of CD30, which activated NF-kappaB signalling
- CD30-L/CD30 and IL-6/IL-6R systems could play a major role in the pathogenesis of Graves'disease (GD), but the expression of CD30L/CD30 and IL-6/IL-6R in Hashimoto's thyroiditis (HT) suggests that Th2 mechanisms are involved in tissue damage.
- Good HLA matching seems to be effective in neutralizing the negative effect of a high pretransplant serum CD30.
- Soluble CD30 could be an important biomarker for an immune system environment conducive to B cell hyperactivation and the development of AIDS-associated B cell lymphoma
- Findings provide additional evidence that CD30 expression is not restricted to neoplasms of lymphoid origin.
- elevated soluble CD30 and neopterin predict graft deterioration by chronic allograft nephropathy
- Patients positive for sCD30 contents are at high risk for the development of donor-specific HLA antibodies and acute rejection after kidney transplantation.
- Measurement of plasma CD30 is a useful procedure for the recognition of rejection in its earliest stages.
- Significant differences were found between systemic lupus erythematosus patients and controls (p=0.0001).
- Increase of CD30 expression is associated with advancement of Hodgkin's disease. '
- Neither pre- nor posttransplantation sCD30 levels were associated with acute rejection in liver transplant patients.
- High levels of sCD30 before heart transplant may be associated with greater immunologic ability and therefore produce a protective effect on the development of infection.
- data show that sCD30 level is significantly higher in non-healing patients compared to those of patients with acute disease. This finding suggests a possible association between sCD30 level and clinical manifestation of the Leishmania tropica infection.
- thioredoxin-1 affects CD30-dependent changes in lymphocyte effector function
- soluble serum CD30 may have a role in rejection of kidney transplants
- Pregnant women with pyelonephritis had a significantly higher median serum concentration of CD30 antigen than those with a normal pregnancy
- Patients with preeclampsia and those who deliver an SGA neonate had a significantly lower serum concentration of sCD30 than normal pregnant women.
- Release of circulating sCD30 is a prominent feature of hepatic allograft rejection, which may be a useful markers for its diagnosis.
- high levels of sCD30 in the common variable immunodeficiency patients with splenomegaly and the presence of lymphoma in a patient with the highest level of sCD30 may suggest a soluble form of this marker as a prognostic tool in such diseases
- constitutive action of aberrantly expressed JunB on hypomethylated CD30 CpG islands of lymphocytes triggers CD30 induction and initiates activation of the JunB-CD30-JunB loop, essential to the pathogenesis of HL and ALCL
- study identified the major CD30 gene promoter microsatellite binding activity as transcription factor Yin Yang 1; study also concludes that CD30-MS length per se is not a major driver of increased CD30 expression in anaplastic large cell lymphoma
- results strongly suggest sCD30 levels of lung transplant patients increase several months prior to clinical evidence of Bronchiolitis Obliterans Syndrome (BOS); rise in serum sCD30 levels can be used as a marker to detect patients at risk to develop BOS
- There is an important role for CD30 in thymic selection.
- Serum CD30 may represent a novel marker for surveillance of hepatic cirrhosis in transplant recipients with chronic hepatitis c virus infection.
- we investigated CD30 signaling in Hodgkin's and ALCL cell lines
- data suggest that the expression of CD30 and CD57 cell markers on T cells could reflect circulating effector T cell early activation in the allergic airway disease.
- In patients with metastatic breast cancer, determining the serum neopterin levels may be useful in estimating survival
- Detection of HLA class II antibodies and serum CD30 measured at least 1 year post-transplant cab predict a subsequent outcome up to 6 years after kidney transplantation.
- Pretransplant CD30 serum concentrations were not associated with deceased-donor kidney graft function at 3 years after transplantation.
- results suggested a possible role of cd30 and cd30L in the pathogenesis of acute leukemia
- sCD30 levels are significantly higher in patients with hymenoptera venom allergy and indirectly confirms a preferential T(H)2-type cytokine production in these patients.
- This paper describes two cases of superficial fungal infection of the skin that demonstrate prominent expression of CD30 within the dermal inflammatory infiltrates.
- Soluble CD30 cannot be used as a biomarker to predict bronchiolitis obliterans after lung transplantation.
- Increased serum CD30 levels in kidney transplantation patints were observed among patients who were panel-reactive antibody-positive, cytomegalovirus antigens or antibodies positive, on long-term dialysis, and
- Serum levels after kidney transplantation predicts acute rejection episodes.
- identification of aryl hydrocarbon nuclear translocator(ARNT) as a CD30-interacting protein that modulated activity of the RelB subunit of NF-kappaB; findings indicate ARNT functions in concert with RelB in a CD30-induced negative feedback mechanism